Month: January 2026

EDAP Announces Preliminary Record Fourth Quarter and Full Year 2025 HIFU Revenue; Issues 2026 Revenue Guidance 36% to 38% Annual YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in Number of U.S. Focal One Procedures 69% Annual YoY Growth in Focal One System Placements 28% Q4 YoY Growth in U.S. Procedures Highlights Accelerating Quarterly Procedure Growth AUSTIN, Texas, January 12, 2026 — EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced select preliminary unaudited financial and operational results highlighting record fourth quarter and full-year 2025 HIFU revenue, driven by strong system placements and accelerating procedure growth. The Company also issued initial worldwide revenue guidance for 2026. For the...

– ARCALYST® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth –– ARCALYST 2026 net product revenue expected to be $900 – $920 million –– KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 –– KPL-1161 Phase 1 trial planned to initiate by year end –– Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today provided a corporate update. “IL-1α & IL-1β inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis....

Company to Participate in Fireside Chat at ICR Conference on January 13 RIDGEFIELD, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) (the “Company” or “Chefs’”), a premier distributor of specialty food products in the United States, the Middle East and Canada, today announced its preliminary outlook for fiscal year 2026. Following a strong fourth quarter of 2025 and based on current trends in the business, the Company is providing the following financial guidance for fiscal year 2026:Net sales in the range of $4.35 billion and $4.45 billion; Gross profit to be between $1.053 billion and $1.076 billion; and Adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”), a non-GAAP measure, to be between $276 million and $286 million.The Company’s full year diluted...

WASHINGTON, Jan. 12, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the expansion of its transactions, shareholder activism and issues management capabilities with the appointments of Dan Scorpio and Heather Wilson as Senior Managing Directors within the firm’s Strategic Communications segment. “Guiding a transaction from announcement through close has never been more challenging with complex, intertwined stakeholder risks that pose meaningful threats to successful close and value realization,” said Pat Tucker, Americas Head of M&A and Activism for the Strategic Communications segment at FTI Consulting. “The dedicated, multi-disciplinary M&A team we’ve assembled is unique and enables our clients to understand, anticipate and mitigate risks to capture transaction value. The addition of Heather...

PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) — Urban Outfitters, Inc. (NASDAQ:URBN), a leading lifestyle products and services company which operates a portfolio of global consumer brands including the Anthropologie, Free People, FP Movement, Urban Outfitters and Nuuly brands, today announced net sales for the two and eleven months ended December 31, 2025. Total Company net sales for the two months ended December 31, 2025, increased 9% compared to the two months ended December 31, 2024. Total Retail segment net sales increased 7%, with comparable Retail segment net sales increasing 5%. The increase in Retail segment comparable net sales was driven by mid single-digit positive growth in both digital channel sales and retail store sales. Comparable Retail segment net sales increased 9% at Urban Outfitters, 5% at Free People and 3%...

ISS cites flexibility for NuVista Shareholders to realize certain cash value or continued participation in endorsing the Arrangement Your vote is important – Vote well in advance of the proxy voting deadline on Wednesday, January 21, 2026 at 8:00 a.m. (Calgary Time) NuVista Shareholders are encouraged to make an election with respect to their preferred form of consideration to be received for the Arrangement ahead of the Election Deadline of Wednesday, January 21, 2026 at 4:30 p.m. (Calgary Time) Questions or require voting assistance? Contact Laurel Hill Advisory Group by phone at 1-877-452-7184 (North American Toll Free) or 1-416- 304-0211 (Outside North America), by texting “INFO” to either number, or by email at assistance@laurelhill.comCALGARY, Alberta, Jan. 12, 2026 (GLOBE NEWSWIRE) — NuVista Energy Ltd. (TSX: NVA) (“NuVista”...

HONG KONG, Jan. 12, 2026 (GLOBE NEWSWIRE) — 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider with the inspiration to become a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced that its wholly-owned Finnish subsidiary, Aurora Core Technology Oy, has entered into a 30-year land lease agreement with the City of Mikkeli for a designated data center development site in the Pellosniemi industrial area of Mikkeli, Finland, covering approximately 101,071 square meters.Dr. Tingjun Yang (right), CEO of 3 E Network, signing the land lease agreement with representatives of the City of Mikkeli (left). Following the previously announced Master Services Agreement with Orka...

Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance  Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported preliminary unaudited 2025 revenue results, cash and investments at year end 2025, and provided a corporate update. “In 2025, we delivered another year of significant revenue growth, with preliminary revenue exceeding the top end of guidance,” said...

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for Neurolief’s Proliv™Rx system, a Class III device, as an adjunctive treatment for adult patients suffering from major depressive disorder (MDD) who have failed to achieve satisfactory improvement from at least one previous antidepressant medication, for use at home or in the clinic. This...